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Three hundred seven high risk patients with renal impairment
(serum creatinine 2:1.5 mg/dl) were randomized in a double-blind
manner to either iopamidol (a nonionic, low osmolar radiocon·
trast agent) or diatrizoate (a conventional radiocontrast agent) at
cardiac angiography with subsequent follow-up study of renal
function. Baseline clinical and angiographic variables were similar
in the iopamidol (n =155) and diatrizoate (n =152) groups.
Change in renal function after angiography was less pro-
nounced with iopamidol compared with diatrizoate as measured
by mean (± SD) increase in 24 h serum creatinine (O.ll ± 0.2
versus 0.22 ± 0.26 mg/dl, p < 0.001), mean maximal increase in
serum creatinine (0.2 ± 0.44 versus 0.38 ± 0.73 mg/dl, p <
0.0001) and percent of patients with a maximal increase in serum
Renal dysfunction due to radiocontrast media is a major
cause of hospital-acquired acute renal insufficiency (1).
Standard ionic radiocontrast agents used over the last few
decades are the salts of negatively charged, iodinated, or-
ganic compounds. These agents have high osmolarity (1,500
to 1,800 mOsm/liter) compared with biologic solutions. In
recent years, new radiocontrast agents with significantly
lower osmolarity, many without ionic charge, have been
introduced and become widely utilized. Of significant inter-
est to the cardiologist, these new agents generally cause
fewer hemodynamic and electrocardiographic changes dur-
ing angiography than do standard contrast media (2,3).
A major question concerning these new agents is their
relative nephrotoxicity. A recent large scale study (4) of
patients with predominantly normal renal function suggested
no difference in nephrotoxicity between iopamidol, a new
agent with low osmolarity and nonionicity, and diatrizoate, a
standard contrast agent. However, clinically significant con-
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creatinine >0.5 mg/dl (8% versus 19%, p < 0.01). Such differ-
ences could not be documented in diabetic patients using insulin.
There was no significant difference between agents in the number
of patients developing clinically severe acute renal dysfunction.
It is concluded that iopamidol is less nephrotoxic than diatri-
zoate in high risk patients at cardiac angiography. However, the
dift'erence in nephrotoxicity is small, of no major clinical signifi-
cance in the majority of high risk patients and could not be
documented in insulin-using diabetic patients. Iopamidol may be
the preferred agent in certain patients with advanced renal
impairment, but further study is warranted.
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trast nephropathy usually occurs in patients with preexisting
renal impairment. The goal of this randomized double-blind
investigation was to compare the relative nephrotoxicity of
iopamidol and diatrizoate in high risk patients with preexist-
ing renal insufficiency undergoing cardiac angiography.
Methods
Study patients. All patients undergoing cardiac catheter-
ization at the Mayo Clinic from February 1987 through
March 1989 were considered for entry into this study. Study
candidates met the following criteria: 1) preexisting renal
impairment defined as a recent (obtained in nearly all pa-
tients within 48 h of catheterization) serum creatinine
>1.5 mg/dl (recruitment value) with the patient not on
dialysis; 2) absence of significant heart failure or severe
aortic stenosis at the time of catheterization (clinical indica-
tions to consider a radiocontrast agent with low osmolarity
in our laboratory); 3) the patient was not receiving medica-
tions with significant nephrotoxicity (for example, gentami-
cin); and 4) the patient or family was able and willing to give
signed consent to participate in study.
Study protocol. Patients were generally recruited to the
study the night before coronary angiography. Patients were
optimally hydrated in an individual fashion at the discretion
of the attending physician and angiographer. Proper hydra-
tion was individualized but generally involved unrestricted
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oral fluid intake (if not clinically deleterious) until midnight
before cardiac catheterization, ~ procedure that maintained
good urine output. Intravenous fluids were administered
starting the night before cardiac catheterization if the patient
was unable to maintain oral intake or begun immediately
before cardiac catheterization. The amount of intravenous
fluids given in the immediate pericatheterization period was
individualized on the basis of clinical status. Fluid balance
was monitored and recorded by nursing staff and catheter-
ization laboratory personnel. Left ventricular end-diastolic
pressure was recorded before radiocontrast administration
in those patients undergoing left ventriculography. The
responsible staff angiographer was able to cancel an individ-
ual patient's participation in the study if it was believed that
a particular radiocontrast agent should be utilized in the
context of the patient's clinical problem.
At the beginning of the cardiac catheterization procedure
and before the administration of contrast material, a blood
sample for measurement of the baseline serum creatinine
was obtained. Patients were randomized in a double-blind
manner to undergo angiography with either iopamidol
(lsovue-370) or diatrizoate (Renografin-76). Patient random-
ization was stratified with respect to the presence of in-
sulin-treated diabetes or recruitment serum creatinine
>3 mg/dl to ensure that similar numbers of patients with
these abnormalities were included in both contrast groups.
Cardiac catheterization was performed in a standard
manner by either the Sones or the Judkins technique. The
exact procedures performed (that is, left ventriculography,
aortography, coronary angiography, bypass graft angiogra-
phy, angioplasty and so on) and amount of contrast medium
administered were dependent on the clinical status of the
patient and at the discretion of the responsible angiographer.
On the morning after angiography, a follow-up blood
sample was obtained for determination of the serum creati-
nine level (defined as the 24 h sample). Depending on the
exact timing of cardiac catheterization and blood collection,
this sample was obtained 18 to 30 h after cardiac angiogra-
phy. Additional follow-up serum creatinine determinations
were obtained in all patients with clinical evidence of acute
renal dysfunction and at the discretion of the primary service
in other patients.
Data collection and analysis. Demographic, clinical,
angiographic and nephrologic data were compiled in all
study patients. Alterations in renal function after angiogra-
phy were measured by the change in an individual patient's
serum creatinine level compared with the baseline value
obtained immediately before angiography. Specifically com-
pared between the two contrast groups were the percent of
patients with a >0.5 mg/dl increase in serum creatinine at
24 h after angiography, the percent of patients with a >0.5
and> 1 mg/dl maximal postangiographic increase in serum
creatinine, the mean change in serum creatinine at 24 h after
angiography and the mean maximal postangiographic change
in serum creatinine. The maximal change in serum creatinine
was defined as the largest change in serum creatinine ob-
tained 1to 5days after coronary angiography compared with
the baseline level. Serum creatinine levels obtained after an
additional radiocontrast procedure or major surgery (that is,
coronary bypass in most cases) were not considered because
of the possible effects of these procedures on renal function.
For example, if a patient underwent cerebral angiography
48 h after coronary angiography, serum creatinine levels
obtained after cerebral angiography were not considered in
determining a patient's maximal increase in serum creati-
nine. Multiple clinical variables (Table 1) were statistically
examined to detect any influence of these variables on the
change in serum creatinine in the two contrast groups.
Statistical design. Study cohort size was estimated on the
basis of data from a retrospective study (5) performed at the
Mayo Clinic investigating contrast nephropathy in high risk
patients with baseline serum creatinine levels >2 mg/dl at
cardiac angiography with diatrizoate. In this study, 30% of
patients had an increment in serum creatinine >0.5 mg/dl at
1day after angiography and 22% of patients had a maximal
increase of > I mg/dl. Assuming similar changes in serum
creatinine in patients studied with diatrizoate in the current
study, sample sizes necessary to detect a 50% (p < 0.05)
difference in the degree of nephrotoxicity between diatri-
zoate and iopamidol were estimated. Contrast groups com-
prising 105 patients were estimated to yield a 90% chance of
detecting a 0.25 mg/dl difference in mean creatinine at 24 h
between the groups. Contrast study groups of 120 and 160
patients were estimated to yield an 80% and 90% chance,
respectively, of detecting a statistical difference in the prev-
alence of an increase in 24 h creatinine >0.5 mg/dl.
The two sample t test was used to compare mean values
and the Wilcoxon rank sum test to compare median values
when the distribution of variables was non-Gaussian. Anal-
ysis of variance of the rank transformation of the individual
changes in serum creatinine was used to multivariately
analyze the change in serum creatinine as a function of
contrast type, insulin-treated diabetes and recruitment se-
rum creatinine 2:3 mg/dl. Values are expressed as mean
± SD. A p value < 0.05 was considered significant.
This study was fully approved by the Mayo Clinic Insti-
tutional Human Research Review Committee in February
1987 before the start of the study.
Results
Characteristics of study groups (Table 1). During the
period from February 1987 through March 1989,325 patients
were initially recruited to participate in this study. Ten
patients were excluded from randomization at the time of
cardiac angiography because the angiographer believed a
specific contrast agent was indicated. Eight patient recruit-
ments represented an individual patient being recruited
multiple times to the study. Only a patient's first participa-
tion in the study was considered. Thus, 307 individual
patients were recruited into the study, were randomized and
underwent cardiac angiography with either iopamidol or
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Table 1. Comparison of Clinical Variables for the Two
Contrast Groups
Iopamidol Diatrizoate
Group Group
Mean age (yr) 68 69
Weight (kg) 81 80
Mean body surface area (m2) 1.92 1.91
% Male 83 80
Clinical history (% patients)
History of heart failure 36 36
NYHA functional class at angiography
I. II 86 84
III. IV 14 16
Hypertension 66 66
Diabetes mellitus
Total 24 23
Insulin-treated 13 13
Coronary artery disease 94 90
Peripheral vascular disease 26 25
Medications (% patients)
Digoxin 26 19
Diuretic drug 50 55
Beta-adrenergic blocker 37 32
Vasodilator (heart failure) 9 7
Antihypertensive agent 16 20
Aspirin 34 24
Dipyridamole 25 18
Nonsteroidal anti-inflammatory 6 5
medication
Calcium channel blocker 60 66
Mannitol 5 7
Laboratory findings
Proteinuria (2-4+, % patients) 15 12
Mean uric acid (mg/dl) 7.7 7.7
Cardiomegaly on chest roentgenogram 23 20
(% patients)
Mean serum creatinine (mg/dl)
Recruitment 2.01 2.04
Baseline 1.83 1.85
Angiography (% patients or as noted)
Coronary angiography 99 100
Left ventriculography 55 59
Mean LVEDP (mm Hg) 23 21
Mean LVEF (%) 57 59
Angioplasty 10 7
Mean dose of contrast medium (ml) 134 144
Surgery after angiography 25 28
(% patients within 5 days)
LVEDP =left ventricular end-diastolic pressure; LVEF =left ventricular
ejection fraction; NYHA = New York Heart Association.
diatrizoate. Serum creatinine levels were obtained immedi-
ately before angiography (baseline) in 305 patients (99%),
24 h after angiography in 294 patients (96%) and after 24 h
but within I week after angiography in 191 patients (62%).
After excluding patients with additional contrast study or
major surgery soon after cardiac angiography, determination
of the increase in 24 h serum creatinine was possible in 283
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patients (92%) and increase in maximal serum creatinine in
289 patients (94%).
The mean age of the study patients was 68 years (range 34
to 90); 81% were men. One hundred fifty-five patients were
randomized to cardiac angiography with iopamidol and 152
with diatrizoate. Demographic, clinical and angiographic
data in both groups are shown in Table I. There were no
significant differences in any of these variables between the
groups. The mean recruitment serum creatinine in the study
patients was 2.02 mg/dl (range 1.5 to 8.8).
Alterations in renal function (Table 2). Mean baseline
serum creatinine (obtained immediately before angiography)
decreased slightly from the recruitment value to 1.84 mg/dl.
This likely reflected the vigorous hydration that is recom-
mended in most patients with renal impairment undergoing
radiologic study with contrast medium. The mean increase in
serum creatinine 24 h after angiography was 0.11 ± 0.2 mg/dl
in patients who received iopamidol compared with 0.22 ±
0.26 mg/dl in patients who received diatrizoate, a highly
significant difference (p < 0.001). There was a >0.5 mg/dl
increase in serum creatinine at 24 h in 5% of patients
receiving iopamidol compared with II% receiving diatri-
lOate (p = 0.07). The mean maximal rise in serum creatinine
after angiography was 0.20 ± 0.44 mg/dl in the iopamidol
group compared with 0.38 ± 0.73 mg/dl in the diatrizoate
group, a highly statistically significant difference (p <
0.0001). Eight percent of patients receiving iopamidol had a
maximal increase in creatinine >0.5 mg/dl compared with
19% of patients receiving diatrizoate (p < 0.01).
Acute renal failure, defined as a maximal increase in
serum creatinine > I mg/dl, occurred in 5 patients (3%)
receiving iopamidol compared with 10 (7%) receiving diatri-
lOate (p = 0.16, [NS]) (Table 2). Dialysis was necessary in
two patients receiving diatrizoate and one receiving iopam-
idol. Clinical data regarding the 15 patients with a maxi-
mal increase in serum creatinine >1 mg/dl are outlined in
Table 2.
Clinical variables and renal function. Hydrational status
was monitored, with no significant differences observed
between the two groups. Mean measured fluid intake the day
of angiography in the iopamidol group was 2.2 liters com-
pared with 2.3 liters in the diatrizoate group. Mean measured
urine output on the day of angiography was 2 liters in both
groups. In patients undergoing ventriculography, mean left
ventricular end-diastolic pressure was similar in the two
contrast groups (Table I). There was no significant differ-
ence in mean contrast dose (mean dose 144 ml diatrizoate
versus 134 ml iopamidol) administered to the two groups.
There was no relation of dose of contrast medium admin-
istered or baseline serum creatinine to change in serum
creatinine in both contrast groups. However, there were
proportionally many fewer patients with severe baseline
renal dysfunction (creatinine >3 mg/dl) and these patients
did tend to receive lower doses of contrast agent (correlation
coefficient r = -0.27, p = 0.0001) than patients with minimal
baseline renal dysfunction.
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Table 2. Clinical Profile of 15 Patients With Acute Renal Failure After Angiography
Pt Class Contrast Contrast
Creatinine (mg/dll
No. NYHA DM Type Dose (mil Baseline Maximal Oliguria Dialysis
J III D 270 1.8 8.3 + +
2 + I 175 2.3 5.7 +
3 III + I 155 1.5 2.6
4 III + D 60 2.7 3.9
5 + D 315 1.6 2.6
6 + D 115 3.6 5.3
7 + I 80 3.6 4.6
8 II D 80 4.3 7.0
9 D 70 2.2 3.2
10 + I 90 7.1 10.5 + +
11 D 70 6.5 8.8 +
12 III + D 150 2.0 3.6
13 D 120 5.4 9.1 +
14 IV I 150 1.9 2.9
15 IV D 250 1.4 3.6
D = diatrizoate; DM = insulin-treated diabetes mellitus; I = iopamidol; NYHA = New York Heart Association functional class-no entry in this column
denotes no prior history of heart failure; Pt = patient; + = present.
The clinical variables listed in Table 1 were analyzed to
determine any possible associations with maximal increase
in serum creatinine after angiography in the two contrast
groups. An association with maximal increase in serum
creatinine was noted only in a subgroup of patients with
diabetes. Diabetic patients who used insulin had a statisti-
cally greater postangiographic maximal increase in serum
creatinine compared with other study patients (p = 0.001).
Baseline renal dysfunction was greater in this subgroup
(mean baseline creatinine 2.4 versus 1.76 mg/dl in others)
and likely influenced the greater degree of contrast-related
renal dysfunction. The degree of baseline renal dysfunction
in this diabetic subgroup was equivalent in both contrast
groups. In addition, there was no difference in the degree of
nephrotoxicity of iopamidol compared with diatrizoate in
this diabetic subgroup. In insulin-using diabetic patients,
there was a mean maximal increase in creatinine after
angiography of 0.6 ± 1.02 mg/dl with iopamidol compared
with 0.54 ± 0.51 mg/dl with diatrizoate (p = 0.36 [NS]).
In the remaining study patients, there was a mean maxi-
mal increase in creatinine of 0.13 ± 0.2 mg/dl with iopamidol
compared with 0.36 ± 0.76 mg/dl with diatrizoate (p <
0.0001). In insulin-using diabetic patients, there was a
>0.5 mg/dl maximal increase in serum creatinine in 30% of
the iopamidol group compared with 40% of the diatrizoate
group (p = 0.51 [NS]). In the remaining study patients, there
was a maximal increase in creatinine >0.5 mg/dl in 5% with
iopamidol and 16% with diatrizoate (p < 0.004).
The maximal increase in serum creatinine plotted against
recruitment serum creatinine is graphically displayed for the
two contrast groups (Fig. 1) with respect to the presence or
absence of diabetes requiring insulin. Four quadrants are
constructed in each group, with divisions at recruitment
serum creatinine = 3 mg/dl and maximal increase in serum
creatinine = 0.5 mg/dl. In all graphs, but especially in Figure
lA and B (patients without diabetes requiring insulin), the
great majority of patients are in the lower left quadrant,
denoting recruitment serum creatinine levels between 1.5
and 3 mg/dl and a maximal increase in serum creatinine
<0.5 mg/dl. Figure IB is noteworthy in that no patient in this
subgroup (iopamidol, no diabetes requiring insulin) had a
maximal increase in serum creatinine >1 mg/dl and no
patient with a recruitment serum creatinine >3 mg/dl had a
maximal increase in creatinine >0.5 mg/dl.
Multivariate analysis. Analysis of variance was utilized
to multivariately analyze the effects of type of contrast
agent, diabetes mellitus requiring insulin and presence of
severe renal insufficiency (recruitment serum creatinine
>3 mg/dl) on the maximal change in serum creatinine after
angiography. A greater maximal change in serum creatinine
was independently related to the use of diatrizoate (p =
0.0001), presence of diabetes requiring insulin (p = 0.0006)
and presence of severe preexisting renal insufficiency (p =
0.034).
Discussion
Iopamidol versus diatrizoate. The major finding of this
study is that in patients with preexisting renal insufficiency
undergoing coronary angiography, iopamidol is less nephro-
toxic than is diatrizoate. The increase in 24 h serum creati-
nine (0.11 ± 0.20 versus 0.22 ± 0.26 mg/dl) , maximal
increase in serum creatinine (0.20 ± 0.44 versus 0.38 ±
0.73 mg/dl) and percent of patients with maximal increase in
serum creatinine >0.5 mg/dl (8% versus 19%) were all
significantly lower in the iopamidol group than in the diatr-
izoate group. However, this observed difference in nephro-
toxicity was small when considering the absolute difference
in the changes in serum creatinine between the two contrast
groups, and there was no observed difference in nephrotox-
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Figure 1. Maximal increase in serum creatinine plotted against
recruitment serum creatinine levels for patient subgroups A (dia-
trizoate, no insulin-treated diabetes), B (iopamidol, no insulin-
treated diabetes), C (diatrizoate, insulin-treated diabetes) and D
(iopamidol, insulin-treated diabetes). Dashed lines are drawn at
recruitment serum creatinine = 3 mg/dl (vertical) and maximal
increase in serum creatinine = 0.5 mg/dl (horizontal).
icity between the contrast agents in diabetic patients using
insulin. In addition, there was no statistically significant
difference between the two agents in the number of patients
developing pronounced renal toxicity, defined as a maximal
increase in serum creatinine > 1 mgldl.
Contrast nephropathy: background. Contrast nephrop-
athy has become an important cause of acute renal insuffi-
ciency because of the large number of radiocontrast proce-
dures currently utilized in modern medical practice.
Clinically significant contrast nephropathy is exceedingly
rare in patients with normal renal function, but occurs more
frequently in those with preexisting renal impairment, espe-
cially in the setting of diabetes mellitus (6-9). The exact
mechanism of contrast nephropathy is uncertain and may
vary in different patients. Standard iodinated contrast agents
have high osmolarity and are ionic in composition. High
osmolarity is postulated to be a contributing factor in con-
trast nephrotoxicity. Diatrizoate is the sodium and methyl-
glucamine salt of diatrizoic acid with an osmolarity of
1,500 mOsm/liter. Several new contrast agents (including
iopamidol) have significantly lower osmolarity and are with-
out ionic charge in solution. The formulation of iopamidol
(Isovue-370) utilized in this study has an osmolarity of
796 mOsm/liter.
Previous investigations. Initial laboratory and small clin-
ical studies « 100 patients) (10-17) have reached varied
conclusions in investigating the relative nephrotoxicity of
the new contrast agents compared with standard agents.
Recently, several large clinical studies examined the relative
nephrotoxicity of ionic and nonionic contrast media in
patients undergoing cardiac angiography. In patients having
cardiac catheterization and angiography with iopamidol (18),
6% of patients developed a postangiographic maximal in-
crease in creatinine >0.5 mgldl and 1.4% a maximal increase
> 1mgldl. No patient developed oliguria or needed dialysis.
Regression analysis showed that the risk of nephrotoxicity
increased exponentially when the baseline serum creatinine
was> 1.2 mg/dl. In a second study by the same investigators
(4), the degree of nephrotoxicity of iopamidol and diatrizoate
was compared in a randomized trial in a general group of
patients undergoing cardiac catheterization. In this study of
patients with predominantly normal renal function, there
was no difference in nephrotoxicity between the two agents.
The investigators (4) and the authors of an accompanying
editorial (19) pointed out that these findings may not apply to
patients with preexisting renal insufficiency. An additional
important finding in that study (4) was that heart failure and
diabetes mellitus did not enhance the risk of contrast
nephropathy in patients with normal renal function.
In a recent series examining the influence of diabetes and
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preexisting renal influence on contrast nephropathy, the
authors (20) commented that low osmolar contrast media did
not appear to be less nephrotoxic compared with conven-
tional agents. However, <30% of the patients in their study
received a low osmolar contrast agent, and patients were not
randomized with respect to the type of contrast agent
administered. The authors (20) concluded that additional
study of the nephrotoxicity of the new agents was necessary.
Another recent series (21) compared low osmolar and con-
ventional contrast media in patients with insulin-dependent
diabetes mellitus undergoing high dose urography. There
were no clinical differences in nephrotoxicity between the
two agents in this group of patients with primarily normal
renal function.
Gomes et al. (22) reported on 145 patients who underwent
various angiographic procedures with the nonionic agent
iohexol with follow-up study of renal function. Acute renal
dysfunction (increase in serum creatinine by 50% or 1mg/dl)
occurred in 5.5% of patients. In contrast, 10% of an histor-
ical control group of 202 patients studied with a standard
ionic agent developed acute renal dysfunction. The investi-
gators (22) recommended a randomized trial to document a
possible advantage of nonionic contrast media.
Present investigation. Our study was designed to examine
the relative nephrotoxic effects of iopamidol and diatrizoate
in a high risk group of patients studied with extreme caution
in our cardiac catheterization laboratory. Our approach in
such patients during the execution of this study was to
implement proper hydration and to try to reduce the amount
of contrast medium administered. Although the dose of
contrast medium administered may not be a critical factor in
patients with normal renal function (23), we (5,24) believed
that large contrast doses may enhance the risk of nephrotox-
icity in patients with preexisting renal insufficiency at angi-
ography. This latter concern likely explains why the mean
dose of contrast medium administered was 137 ml in our
study compared with 177 and 201 ml, respectively, in the two
recent studies (4,18) involving a general group of patients
undergoing cardiac catheterization.
Interpretation and recommendations. Our data suggest
that iopamidol is less nephrotoxic than diatrizoate in patients
with preexisting renal impairment. However, this difference
is small and of little clinical consequence in most patients
(Fig. 1). Also, in patients with perhaps the greatest risk for
contrast nephropathy, insulin-using diabetic patients with
renal impairment, we were unable to determine any differ-
ence in nephrotoxicity between the two agents. This latter
finding, however, should be interpreted with caution be-
cause of the overall small number of patients with insulin-
treated diabetes mellitus (n = 40) included in our study. We
believe that in the majority of high risk patients (serum
creatinine 2: 1.5 mg/dl) undergoing cardiac angiography, the
risk of clinically significant renal toxicity is low when pa-
tients are properly hydrated and contrast exposure is mini-
mized. In such patients, the type of angiographic dye admin-
istered may not be the most important factor.
Clinical considerations other than contrast nephropathy
should also be weighed in the selection of contrast agent
used. However, it may be prudent to consider an agent like
iopamidol in patients with advanced renal impairment and
very limited renal reserve in whom a relatively small detri-
mental effect on renal function may be of significant clinical
consequence. Although there were few patients with ad-
vanced renal impairment (creatinine >3 mg/dl) in our study,
this approach appears justified (Fig. 1) at least in patients
without insulin-treated diabetes mellitus. Clearly, additional
study of larger numbers of patients with advanced renal
impairment and patients with diabetes is warranted.
The selective use of a low osmolar contrast medium is
important in view of cost-containment measures in modern
medical practice. Currently, the low osmolar contrast agents
are approximately 7 to 15 times as expensive as standard
ionic contrast media in the United States. Although the cost
of contrast medium is a small fraction of the total cost of
coronary angiography, we have estimated that the use oflow
osmolar contrast media in all patients (approximately 5,000/
year) undergoing cardiac angiography at our institution
would yield an additional yearly expense of approximately
$900,000. The definition of subgroups in which there is a
clinical advantage of low osmolar agents as well as sub-
groups with no clear-cut clinical advantage is important for
maximization of health care resources.
Limitations. Although we studied 307 patients, this pa-
tient number was too small to completely compare the
prevalence of clinically important nephrotoxicity of the two
agents. The rates of clinically important nephrotoxicity were
less than anticipated (see Methods), likely as a result of
inclusion of patients with baseline serum creatinine levels in
the 1.5 to 1.9 mg/dl range in the current study but not in the
retrospective study (5) from which estimates were made. It
is speculative whether greater patient numbers would have
shown iopamidol to be the superior agent in this regard.
Hundreds of additional patients might be required to deter-
mine such possible statistical differences; however, it is not
likely that an expanded cohort of patients would dramati-
cally alter our current conclusions.
Ideally, any study of contrast nephropathy should include
baseline study of multiple variables of renal function with
daily follow-up assessment of renal function in all patients
for 4 to 5 days. Unfortunately, in most clinical settings, this
is not practical or possible. We designed our study on the
basis of data in which current clinical practice is executed.
Serum creatinine was selected as the major variables of renal
function because of its wide utilization and application.
Additional variables of renal function were not studied
because we believed that they would not yield a significant
increment in clinically relevant data above that defined by
serum creatinine. Patients had careful measurement of fluid
balance and baseline and 24 h serum creatinine levels.
Sixty-two percent of the patients had additional follow-up
study of serum creatinine. Ideally, all patients should have
had additional follow-up assessment of renal function. This
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was not possible in many patients who had no evidence of
contrast nephropathy at 24 h after angiography.
Conclusions. This investigation demonstrates that iopam-
idol is less nephrotoxic than diatrizoate in high risk patients
undergoing cardiac angiography. However, this difference in
nephrotoxicity is of little clinical consequence in the major-
ity of high risk patients and cannot be demonstrated in
insulin-using diabetic patients. Iopamidol rather than diatri-
zoate may be the preferred agent in patients with advanced
renal impairment, although this subgroup and patients with
diabetes mellitus merit further study.
We thank Jolene Lillistol and Janet Fogleman for expert secretarial assis-
tance. In addition, we thank the cardiology fellows at the Mayo Clinic;
without their efforts, this study would not have been possible.
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